# A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection

> **NCT00002183** · PHASE1 · COMPLETED · sponsor: **Glaxo Wellcome** · enrollment: 60 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Abacavir sulfate
- **DRUG:** Amprenavir
- **DRUG:** Lamivudine
- **DRUG:** Zidovudine

## Key facts

- **NCT ID:** NCT00002183
- **Lead sponsor:** Glaxo Wellcome
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 60 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002183, "A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00002183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*